Physician profile
Jayne Smith
NPI 1740634690
$1,085.18
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $301 · 2022: $657 · 2023: $127.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $127.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $127.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $375.30 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $209.03 | 2021-2022 | |
| Lucid Diagnostics INC. | $127.34 | 2023 | |
| Ironwood Pharmaceuticals, INC | $79.20 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $61.00 | 2021-2022 | |
| Daiichi Sankyo INC. | $57.37 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $50.57 | 2021 | |
| Redhill Biopharma INC. | $35.68 | 2021-2022 | |
| Gilead Sciences, INC. | $26.78 | 2021-2022 | |
| Pfizer INC. | $26.16 | 2022 | |
| Genzyme Corporation | $19.73 | 2022 | |
| Janssen Biotech, INC. | $17.02 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jayne Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.